Celldex

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celldex and other ETFs, options, and stocks.

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. 

CEO
Anthony S. Marucci
CEOAnthony S. Marucci
Employees
198
Employees198
Headquarters
Hampton, New Jersey
HeadquartersHampton, New Jersey
Founded
1983
Founded1983
Employees
198
Employees198

CLDX Key Statistics

Market cap
3.29B
Market cap3.29B
Price-Earnings ratio
-9.62
Price-Earnings ratio-9.62
Dividend yield
Dividend yield
Average volume
966.95K
Average volume966.95K
High today
$42.75
High today$42.75
Low today
$40.88
Low today$40.88
Open price
$42.35
Open price$42.35
Volume
840.57K
Volume840.57K
52 Week high
$45.14
52 Week high$45.14
52 Week low
$20.37
52 Week low$20.37

Stock Snapshot

As of today, Celldex(CLDX) shares are valued at $41.95. The company's market cap stands at 3.29B, with a P/E ratio of -9.62.

On 2026-08-16, Celldex(CLDX) stock moved within a range of $40.88 to $42.75. With shares now at $41.95, the stock is trading +2.6% above its intraday low and -1.9% below the session's peak.

Trading volume for Celldex(CLDX) stock has reached 840.57K, versus its average volume of 966.95K.

The stock's 52-week range extends from a low of $20.37 to a high of $45.14.

The stock's 52-week range extends from a low of $20.37 to a high of $45.14.

CLDX News

Simply Wall St 4d
Celldex Therapeutics Reported Wider Losses, Is It Still Undervalued?

Advertisement Why Celldex Therapeutics Stock Is Moving After Its Latest Earnings Report Celldex Therapeutics (CLDX) released second quarter and first half 202...

Celldex Therapeutics Reported Wider Losses, Is It Still Undervalued?
Simply Wall St 7d
Why Celldex Therapeutics Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress

Earlier this week, Celldex Therapeutics reported its second quarter 2026 results, showing revenue of just US$22,000 and a net loss of US$73.5 million, alongside...

Why Celldex Therapeutics Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress

Analyst ratings

94%

of 16 ratings
Buy
93.8%
Hold
6.3%
Sell
0%

People also own

Based on the portfolios of people who own CLDX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.